Galderma Stock News

ZUG, Switzerland & IRVINE, Calif.--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced that it has signed an agreement to acquire ZO® Skin Health, a leading physician-dispensed skincare brand built on clinical science and protocol-based daily care, from its shareholders, including funds managed by Blackstone Tactical Opportunities (“Blackstone”) and the Obagi family. Founded by dermatologist ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced new global research revealing that more than half (56%) of women first put menopause-related skin changes down to general ageing, while only less than a third of women (29%) initially recognized the link to menopause.1 The research shines a light on ‘The Menopausal Skin Misread', showing how aesthetic changes in the skin li...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new data regarding the use of Nemluvio for atopic dermatitis and prurigo nodularis to be presented at the 2026 Fall Clinical Dermatology Conference, taking place from October 08-11 in Las Vegas, United States. This includes a new post-hoc analysis from the ARCADIA LTE study showin...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, is presenting new three-year data from the ARCADIA long-term extension study, demonstrating that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atop...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, will present 19 abstracts and deliver a broad scientific education program at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. Through these activities, Galderma will showcase how it continues to advance its pipeline and the science of dermatology, deepening understanding...

Galderma's CEO said the Swiss skincare firm plans to expand its ​product range at some point but ‌would remain cautious not to lose its focus, speaking in an interview with Swiss ​newspaper Finanz und Wirtschaft published on ​Friday.

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patients in China.1 The study met its primary endpoint, demonstrating the effectiveness and safety of Restylane Volyme versus a no-treatment control, while also achieving high patient and investigator s...

Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.